Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EPS (Basic) (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed EPS (Basic) for 6 consecutive years, with -$1.29 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) fell 1942.86% to -$1.29 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.4, a 91.85% increase, with the full-year FY2024 number at -$11.45, up 83.74% from a year prior.
  • EPS (Basic) was -$1.29 for Q3 2025 at Ensysce Biosciences, down from -$0.79 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.48 in Q4 2022 to a low of -$67.08 in Q4 2023.
  • A 5-year average of -$7.89 and a median of -$1.39 in 2025 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 286300.0% in 2021, then surged 108.05% in 2024.
  • Ensysce Biosciences' EPS (Basic) stood at -$28.62 in 2021, then surged by 105.17% to $1.48 in 2022, then plummeted by 4632.43% to -$67.08 in 2023, then skyrocketed by 95.63% to -$2.93 in 2024, then soared by 55.97% to -$1.29 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's EPS (Basic) are -$1.29 (Q3 2025), -$0.79 (Q2 2025), and -$1.39 (Q1 2025).